HMPL-004 Chosen as a Top 10 Inflammatory/Autoimmune Projects to Watch by Windhover and Healogix

Shanghai: Monday, October 18, 2010: Hutchison MediPharma today announced that its lead drug candidate for Inflammatory Bowel Disease (IBD), HMPL-004, has been chosen by Windhover Information, Inc. and Healogix, LLC as one of the top Top 10 Inflammatory/Autoimmune Projects to Watch. This represents a significant industry honor.

HMPL-004 is a novel, oral IBD therapy that has shown a remarkable efficacy and safety profile in two Phase II trials for the treatment of Ulcerative Colitis (UC) and Crohn’s Disease (CD).  Recently, in November 2009 a global Phase IIb UC clinical trial was highly successful, and the results were presented in a Distinguished Plenary oral presentation at Digestive Disease Week in May 2010.

As one of the first oral drug candidates classified as a botanical to enter global Phase III studies, HMPL-004 has enjoyed special attention as a pioneering project and has previously received several prestigious awards and nominations internationally and in China.

HMPL-004 was chosen as a Top 10 Inflammatory/Autoimmune Project by an independent committee assembled by Windhover Information, the publishers of In Vivo and Startup, and Healogix, specialists in marketing research and consulting for the pharma and biotech industries.  The committee’s criteria included each project’s large unmet market need, the strength of the company and the science, the diversity of current and future indications, and the opportunities for multi-level partnering.

Samantha Du, Chief Executive Officer of Hutchison MediPharma, said: “This Windhover award is an important and highly prestigious honor.”  She added, “This substantial recognition of HMPL-004, alongside the praise and acknowledgement it received at Digestive Disease Week, further underscores the compound’s potential for these unmet medical needs.”

About Windhover Information and TA Partnerships
Since 1989, Windhover Information Inc. has been providing analysis and commentary on health care business strategy, industry dealmaking, marketplace trends, and the world of medical start-ups.  The expertise that its editorial and research staff have developed – now consulted and relied upon by industry executives, consultants, bankers and investors – finds voice in its publications, conferences, and integrated, databases of transactions and commentary.  Itss editorial goal is to clearly present objective, accurate, fundamentally valuable decision-making information.

Windhover Information’s 4th Annual Therapeutic Area Partnerships is one of the industry’s most targeted and efficient partnering meetings for life science companies seeking partnerships.

About HMPL-004
HMPL-004 is an orally active, proprietary botanical product that acts on multiple targets in the pathogenesis of inflammation.  It is a compound extracted from a Chinese herb under controlled conditions and its composition is well characterised.  The anti-inflammation activity of HMPL-004 was originally identified in a cell-based anti-inflammation screening assay at Hutchison MediPharma.

About Inflammatory Bowel Diseases (“IBD”)
Ulcerative Colitis (“UC”) and Crohn’s Disease (“CD”) are the two most common forms of IBD.  The patient population with UC and CD in the United States is estimated to be between 250,000-500,000 and 400,000-600,000 respectively.  The estimated annual new incidences of UC and CD in the US are 2-7 cases per 100,000 and 5-7 cases per 100,000, respectively.  Between 2001 and 2005 it is estimated that the number of patients with UC in the United States increased by approximately 47,000, representing a CAGR of 4% and the number of patients with CD increased by approximately 58,000, a CAGR of 3%.  Information in this paragraph was provided by Cambridge Consultants Limited in 2006.

About Hutchison MediPharma
Hutchison MediPharma is a leading biotechnology company in China.  The Company has a team of well over 200 scientists and staff focusing on discovery and development of botanical drugs, semi-synthetic natural product drugs, and synthetic single chemical entity drugs.  Hutchison MediPharma has a pipeline of single new chemical entity projects in both oncology and auto-immune/inflammatory disease.

Hutchison MediPharma Limited
Building 4, 720 Cai Lun Road
Zhangjiang Hi-Tech Park
Shanghai, China 201203

Tel: +86 21 5079 0088
Fax: +86 21 5079 3900